Stock Research: BB Biotech

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

BB Biotech

SWX:BION CH0038389992
98
  • Value
    98
  • Growth
    94
  • Safety
    Safety
    94
  • Combined
    100
  • Sentiment
    35
  • 360° View
    360° View
    98
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 98 (better than 98% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock BB Biotech are very positive. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for BB Biotech. The consolidated Value Rank has an attractive rank of 98, which means that the share price of BB Biotech is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 98% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 94, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 94. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 35. Professional investors are more confident in 65% other stocks. ...read more

more
Index
SPI
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
98 n/a n/a n/a
Growth
94 n/a n/a n/a
Safety
Safety
94 n/a n/a n/a
Sentiment
35 n/a n/a n/a
360° View
360° View
98 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
61 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
23 n/a n/a n/a
Sentiment
35 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
98 n/a n/a n/a
Growth
94 n/a n/a n/a
Safety Safety
94 n/a n/a n/a
Combined
100 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
90 n/a n/a n/a
Price vs. Earnings (P/E)
26 n/a n/a n/a
Price vs. Book (P/B)
64 n/a n/a n/a
Dividend Yield
100 n/a n/a n/a
Value
98 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
84 n/a n/a n/a
Profit Growth
86 n/a n/a n/a
Capital Growth
48 n/a n/a n/a
Stock Returns
75 n/a n/a n/a
Growth
94 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
97 n/a n/a n/a
Refinancing
45 n/a n/a n/a
Liquidity
100 n/a n/a n/a
Safety Safety
94 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to BB Biotech and broaden your portfolio horizons.

Bachem

SWX:BANB
Country: Switzerland
Industry: Life Sciences Tools & Services
Size: Medium
Full Stock Analysis

Zehnder Group

SWX:ZEHN
Country: Switzerland
Industry: Building Products
Size: Medium
Full Stock Analysis

Ipsen

PAR:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Eurofins Scientific

PAR:ERF
Country: Luxembourg
Industry: Life Sciences Tools & Services
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This stock has excellent financial qualities (value, growth, and safety are high) but a negative professional market sentiment. It suits an investor who believes the negative sentiment is a temporary overreaction and is looking for a financially solid company.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: